We read with interest the paper of Jing et al. 1 dealing with CD49d blockade by natalizumab in patients with multiple sclerosis (MS) resulting in mobilization of progenitors with a distinct phenotype and function. Compared with healthy controls and untreated MS patients, natalizumab treatment increased CD34 þ cells in the peripheral blood and in the BM. Moreover, the CD34 þ cells of natalizumab-treated patients expressed lower levels of adhesion molecules (L-selectin, LFA-1 and PECAM-1) than G-CSF-mobilized CD34 þ cells. Natalizumab is an anti-a4 integrin humanized IgG4 MoAB that blocks a4b1-(also referred as very late activation Ag (VLA)-4 integrin or CD49d) mediated leukocyte migration. It consequently prevents extravasation of all leukocytes except polymorphonuclears that do not express VLA-4.
2 Secondary effects of natalizumab include mild leukocytosis with lymphocytosis and decreased numbers of B and T lymphocytes in the cerebrospinal fluid, 3 but have been poorly investigated. 4 We checked the peripheral blood lymphocytes of seven patients (from a series of 10) 5 before and during Natalizumab All patients had relapsing-remitting MS and were treated with natalizumab according to standard procedures, that is, 300 mg intravenously once a month. Lymphocyte counts were increased in all ( Â 1.5 to 2.5 from baseline), in the first 6 months after therapy, and mainly in the first month (mean: Â 1.63 ± 1.4). All but one patient demonstrated binucleated cells, affecting between 1/500 and 2/100 lymphocytes similar to those observed in persistent polyclonal B cell lymphocytosis with binucleated lymphocytes 6 and strongly expressed IgD after intracytoplasmic labeling. Lymphocyte variations affected mainly B cells with a rising count up to four-fold immediately after treatment initiation. After 1 month therapy, the increase mean was Â 0.38 ± 0.31 with counts ranging from 0.6 to 1.4 Â 10 9 /L (reference range o0.5 Â 10 9 /L). We also observed a moderate increase of CD4 þ T cells, less than two-fold. After 1 month of therapy, the mean increase of CD4 þ T cells was Â 0.49±0.65 (range 0.6-3 Â 10 9 /L (reference range o1.4)). Modifications were less consistent for CD8 þ T cells with an increase in six patients and only marked in two (mean after 1 month therapy Â 0.22±0.34) (Figure 1 ). The immunophenotype of B cells was always CD19 þ ,
In all cases, polyclonality for immunoglobulin (Ig) Kappa/Lambda light chains was found and the expression profile for heavy chains was IgM/IgD coexpression for all patients with IgM dim and IgD bright and CD19 þ CD27-IgD þ coexpression. These results are in favor of a B-cell expansion derived from the naive immature compartment of B cells. Binucleated cells had a B-cell phenotype in all cases. Exploration of leukocyte adhesion and migration molecules included CD29 (intergrins b1 chain), CD11a (LFA1a), CD18 (LFA1b), CD54 (ICAM), CD62E (E-selectin, ELAM-1), CD62L (L-selectin, LAM-1), CD62P (P-selectin, GMP 140), CD103 (aE integrin, HML-1), CD11b (aM, MAC-1), CD11c and CD49d (VLA-4). Reference ranges were determined from 10 patients with MS but no natalizumab treatment. In our seven patients, B cells showed normal expression of CD11a/CD18, CD62L, CD11b and CD103 along with a decreased expression of CD54 and CD62E. T cells demonstrated a close immunophenotype except for a decreased expression of CD29. CD54 was not expressed on either B or T cells (Table 1 ). CD49d expression, calculated as mean fluorescence intensity, was markedly decreased compared with reference samples: 0.57 vs 1.8 for B cells and 0.95 vs 3 for T cells (Table 2) . Integrins are known to interact strongly with other adhesion molecules on the cell's surface, especially via lipid rafts. 7 Although CD49d is the specific target of natalizumab, and therefore is logically modulated on the cells, our results suggest that this disruption of one integrin may also alter the expression of other adhesion molecules. The net result could therefore be, as expected, a defective stimulation potential of B and T cells, along with decreased migration capacities across the blood-brain barrier. 2 In conclusion, our data validate those previously generated by Jing et al. 1 and further study the side effects % of lymphocytes expressing the marker. Median obtained from 10 patients with MS but without natalizumab therapy.
Letter to the Editor of natalizumab on lymphopoiesis of MS patients. The peripheral blood lymphocytosis observed after natalizumab therapy in MS patients appeared as an immediate side effect. The immunophenotypic profile CD5-, CD10-, CD27-, IgM dim and IgD bright is consistent with an immature 'naive' B-cell subset, recently egressed from the BM and not activated (CD25-, CD38 low ). Upregulation of CD4 þ and CD8 þ T cells was less convincing suggesting a different effect of natalizumab on the medullary and thymic environments. The adhesion molecule profile seems to be favorable for the patients, protecting them from progressive multifocal leukoencephalopathy in preventing damaging immune cells from crossing the blood-brain barrier.
8 Table 2 MFI of adhesion molecules Abbreviations: MFI ¼ mean fluorescence intensity; RV ¼ reference value. RV see Table 1 legend.
